Study to test efficacy, safety of injectable cabotegravir compared to daily oral PrEP December 20, 2016 – The first large-scale clinical trial of a long-acting injectable drug for HIV prevention began today. The study, sponsored by the National Institutes of Health, will examine whether a long-acting ...

Lyon, France, December 19, 2016 – POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, announced that ENYO Pharma SA reported that they have initiated a Phase 1 program for EYP001, an FXR ...

A once-daily treatment that demonstrated comparable efficacy with improved renal and bone laboratory safety parameters compared to tenofovir disoproxil fumarate (TDF) FOSTER CITY, Calif., Dec. 19, 2016– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved ...

Webcasts of the presentations from HIV Glasgow are now available to view online at www.hivglasgow.org Posters presented at the congress can be viewed online here. If you didn’t have an opportunity to attend HIV Glasgow, you can get a flavour of the Congress via the Daily News ...

New data released for New York, show that this major city with high HIV prevalence – approximately 120,000 HIV positive people currently live in the city – is steadily reducing the number of new infections. New York is also significant for setting targets for reducing ...

ABIVAX reports new preclinical data supporting ABX464 as HIV functional cure and novel treatment for inflammatory diseases at HIV DART Meeting ABIVAX provides update on clinical development program for ABX464 for functional cure of patients with HIV-infection Original Article

With hepatitis C (HCV) being curable with direct-acting antivirals in eight to 12 weeks or less, the question arises whether we can transplant HCV-positive organs to HCV-negative patients safely with treatment. In a large study of U.S. kidney transplant recipients, five-year graft and patient survival ...

Generic sofosbuvir-based combinations may not perform as well as therapy based on branded sofosbuvir-containing regimens, according to result of a study conducted in Qatar and presented to the recent 2016 AASLD Liver Meeting. People treated with generics were less likely to have a sustained virological ...

The first study to explore United Kingdom men’s perceptions of PrEP – a new HIV prevention treatment – has found that their opinions are negatively influenced by social stigma. The article published in Cogent Medicine provides alarming new evidence that the fight against AIDS in ...

The communities most affected by HIV must be meaningfully involved in the AIDS response if we are to overcome the stigma, discrimination and denial of human rights that continue to put people at risk of HIV and deny them access to HIV prevention and treatment ...

Actor Charlie Sheen revealed this month that he has achieved an undetectable viral load by taking PRO 140, an injectable HIV drug that’s currently being studied, according to a report in the Daily Mail. “It’s impossibly amazing. Personally, I think about how I felt on the ...

The UNITAID HIV rapid diagnostic tests for self-testing Landscape was first published on World AIDS Day in December 2015, as part of an effort to build an understanding of the HIV self-testing market. A second edition was published in July 2016 at the International AIDS ...

A CALL TO ACTION BY THE BEYOND VIRAL SUPPRESSION INITIATIVE Improving Outcomes for People Living with HIV This is a call to action for European governments, international organisations, patient organisations, and the wider health community to align on a new HIV policy agenda that addresses the crucial ...

If approved, SOF/VEL/VOX would be the first once-daily single tablet regimen available as a salvage therapy for patients infected with HCV genotype 1-6 who have failed prior treatment with DAA regimens including NS5A inhibitors FOSTER CITY, Calif.–Dec. 8, 2016– Gilead Sciences, Inc. (Nasdaq: GILD) today announced ...

Global health agencies are succeeding in getting more people with HIV on antiretroviral therapy, a combination of drugs that suppress the virus to undetectable levels in the blood and reduce the risk of transmission to another person. But scientists are beginning to detect a disturbing ...

People who inject drugs (PWID) can have an excellent response to sofosbuvir-based therapy for hepatitis C virus (HCV) infection, Ukrainian research presented to the recent 2016 AASLD Liver Meeting shows. Overall, 93% of people had a sustained virological response 12 weeks (SVR12) after the completion of ...

A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results presented at the 2016 AASLD Liver Meeting in Boston. Studies done in ...

Today, 1st of December, is the World AIDS Day. On this day, every year we remember those who passed away from AIDS and honour those who advocate to fight against the HIV epidemic. SWAN also expresses solidarity with all the people who are affected by ...